Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
CX-5461
Cat No.
CEI-0326
Description
CX-5461 is a potent small-molecule inhibitor of RNA polymerase (Pol) I.
CAS No.
1138549-36-6
Molecular Weight
513.61
Purity
>99%
Storage
2 years at -20 centigrade
Targets
Pol I
Molecular Formula
C27H27N7O2S
Chemical Name
5H-Benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-
Solubility
DSMO
In vitro
CX-5461 is a potent small-molecule inhibitor of RNA polymerase (Pol) I. CX-5461 inhibit Pol I in the HCT-116 cells with IC50 of 142 nM. CX-5461 also inhibit Pol I in melanoma A375 cell line and pancreatic carcinoma MIA PaCa-2 cell line with IC50 of 113 nM and 54 nM.CX-5461 directly targets the Pol I machinery and inhibits Pol I transcription at the initiation stage.CX-5461 inhibits Pol I via disruption of the SL1-rDNA complex. And CX-5461 inhibits Pol I transcription without having an effect on DNA replication, protein translation, and general cellular transcription. As RNA polymerase (Pol) I is a multiprotein complex activated widely in cancer cells, CX-5461 can block cancer cell proliferation. CX-5461 inhibits the initiation stage of rRNA synthesis and induces both senescence and autophagy, but not apoptosis, through a p53-independent process in solid tumor cell lines. For example,CX-5461 induces autophagy but not apoptosis in A375 and MIA Paca-2 cancer cells.
In vivo
In two murine xenograft models of human cancers, pancreatic carcinoma (MIA PaCa-2) and melanoma (A375), CX-5461(50 mg/kg) demonstrated significant MIA PaCa-2 TGI with TGI equal to 69% on day 31.By inhibiting Pol I transcription, CX-5461 produce in vivo antitumor responses against solid tumors.
Download
Download Datasheet